Report of the NIH panel to define principles of therapy of HIV infection

Annals of Internal Medicine

Volumn 128, Issue 12 PART 2, 1998, Pages 1057-1078

  Carpenter, Charles ^a   Feinberg, Mark ^b   Aubry, Wade ^c   Averitt, Dawn ^d   Coffin, John ^e   Cooper, David ^f   Follansbee, Stephen ^g   Hamburg, Peggy ^h   Harrington, Mark ⁱ   Hidalgo, Julia ^j   Jaffe, Harold ^k   Landers, Dan ^l   Masur, Henry ^b   Pizzo, Philip ^m   Richman, Douglas ⁿ   Saag, Michael ^o   Schooley, Robert ^p   Stone, Valerie ^q   Thompson, Melanie ^r   Trono, Didier ^s   Vella, Stefano ^t   Walker, Bruce ^m   Yeni, Patrick ^u   more..

^a BROWN UNIVERSITY   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c Blue Cross/Blue Shield Association   (United States)

^d Women's Info Service and Exchange   (United States)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^h NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

ⁱ Treatment Action Group   (United States)

^j Ctr for AIDS Serv Plan and Devmt   (United States)

^k CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^l UNIVERSITY OF PITTSBURGH   (United States)

^m HARVARD MEDICAL SCHOOL   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^p UNIVERSITY OF COLORADO   (United States)

^q BROWN UNIVERSITY   (United States)

^r AIDS Research Consortium of Atlanta   (United States)

^s SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^t ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^u Medical School Xavier Bichat   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; HEALTH CARE ORGANIZATION; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; VIRUS LOAD; VIRUS REPLICATION;

EID: 15644375194     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-128-12_part_2-199806151-00002     Document Type: Review

References (107)

1. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995;373:117-22.
2. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373:123-6.
3. Embretson J, Zupancic M, Ribas J, et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature. 1993;362:359-62.
4. Pantaleo G, Graziosi C, Demarest J, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature. 1993;362:355-8.
5. Mellors JW, Kingsley LA, Rinaldo CR, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med. 1995; 122:573-9.
6. O'Brien TR, Blattner WA, Waters D, et al. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA. 1996;276:105-10.
7. Jurriaans S, van Gemen B, Weverling GJ, et al. The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course? Virology. 1994;204.223-33.
8. Saksela K, Stevens CE, Rubenstein P, Taylor PE, Baltimore D. HIV-1 messenger RNA in peripheral blood mononuclear cells as an early marker of risk for progression to AIDS. Ann Intern Med. 1995;123:641-8.
9. + lymphocyte counts and the risk of progression to AIDS. N Engl J Med. 1995;334:426-31.
10. O'Brien TR, Rosenberg PS, Yellin F, Goedert JJ. Longitudinal HIV-1 RNA levels in a cohort of homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol. 1998; [In press].
11. Enger C, Graham N, Peng Y, et al. Survival from early, intermediate, and late stages of HIV infection. JAMA. 1996;275:1329-34.
12. Haynes BF, Panteleo G, Fauci AS. Toward an understanding of the correlates of protective immunity to HIV infection. Science. 1996;271:324-8.
13. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med. 1996;335:1091-8.
14. Dickover RE, Dillon M, Gillette SG, et al. Rapid increases in load of human immunodeficiency virus correlate with early disease progression and loss of CD4 cells in vertically infected infants. J Infect Dis. 1994;170:1279-84
15. Mclntosh K, Shevitz A, Zaknun D, et al. Age- and time-related changes in extracellular viral load in children vertically infected by human immunodeficiency virus. Pediatr Infect Dis J. 1996;15:1087-91.
16. Mofenson LM, Korelitz J, Meyer WA, et al. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. J Infect Dis. 1997;175:1029-38.
17. Dickover RE, Dillon M, Leung KM, et al. Early prognostic indicators in primary perinatal HIV-1 infection: importance of viral RNA and the timing of transmission on long term outcome. J Infect Dis. 1998; [In press].
18. Shearer WT, Quinn TC, LaRussa P, et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. N Engl J Med. 1997;336:1337-42.
19. Saag MS, Holodniy M, Kuritzkes DR, et al. HIV viral load markers in clinical practice. Nat Med. 1996;2:625-9.
20. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996;271:1582-6.
21. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995;267:483-9.
22. Raboud JM, Montaner JS, Rae S, Conway B, Singer J, Schlechter MT. Issues in the design of trials of therapies for subjects with human immunodeficiency virus infection that use plasma RNA level as an outcome. J Infect Dis. 1997;175:576-82.
23. Kempf D, Molla A, Sun E, Danner S, Boucher C, Leonard J. The duration of viral suppression is predicted by viral load during protease inhibitor therapy [Abstract]. In: Programs and Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 22-26, 1997.
24. DeGruttola V, for the ACTG Cross Protocol Study Group. Prognostic value of CD4 counts and plasma HIV RNA: an ACTG cross protocol analysis. In: Proceedings of the Public Meeting of the NIH Panel To Define Principles of Therapy of HIV Infection, November 13-14, 1996. Washington, DC: Office of AIDS Research, NIH.
25. Palumbo PE, Raskino C, Fiscus S, et al. Correlation of HIV plasma RNA levels with clinical outcome in a large pediatric trial (ACTG 152) [Abstract]. In: Program and Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 22-26, 1997.
26. + lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: a review. J Infect Dis. 1992;165:352-63.
27. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126:946-54.
28. USPHS/IDSA Prevention of Opportunistic Infections Working Group: 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep. 1997;46(RR-12).
29. El-Sadr W, Oleske JM, Agins BD, et al. Evaluation and management of early HIV infection. Clinical practice guideline no. 7. AHCPR publication no. 94-0572. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services; January 1994.
30. 1995 revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. MMWR Morb Mortal Wkly Rep. 1995;44(RR-4).
31. Schacker T, Hughes J, Shea T, Corey L. Viral load in acute and very early HIV infection does not correlate with disease progression [Abstract]. In: Program and Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 22-26, 1997.
32. Staprans SI, Hamilton BL, Follansbee SE, et al. Activation of virus replication after vaccination of HIV-1 infected individuals. J Exp Med. 1995; 182:1727-37.
33. Stanley SK, Ostrowski MA, Justement JS, et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med. 1996;334:1222-30.
34. Brichacek B, Swindells S, Janoff EN, Pirrucello S, Stevenson M. Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine. J Infect Dis. 1996;174: 1191-9.
35. Raboud JM, Montaner JS, Conway B, et al. Variation in plasma RNA levels, CD4 cell counts, and p24 antigen levels in clinically stable men with human immunodeficiency virus infection. J Infect Dis. 1996;174:191-4.
36. Deeks SG, Coleman RL, White R, et al. Variance of plasma human immunodeficiency virus type 1 RNA levels measured by branched DNA within and between days. J Infect Dis. 1997;176:514-7.
37. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. 1997;387:188-91.
38. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725-33.
39. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337:734-9.
40. Montaner J, Wainberg M. INCAS study results. In: Proceedings of the Public Meeting of the NIH Panel To Define Principles of Therapy of HIV Infection, November 13-14, 1996. Washington, DC: Office of AIDS Research, NIH.
41. Pachl C, Todd JA, Kern DG, et al. Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8:446-54.
42. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol. 1994;32:292-300.
43. Vandamme AM, Van Dooren S, Kok W, et al. Detection of HIV-1 RNA in plasma and serum samples using the NASBA amplification system compared to RNA-PCR. J Virol Methods. 1995;52:121-32.
44. Yen-Lieberman B, Brambilla D, Jackson B, et al. Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group Virology Laboratories. J Clin Microbiol. 1996;34:2695-701.
45. Schuurman R, Descamps D, Jan Weverling G, et al. Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 1996;34:3016-22.
46. Revets H, Marissens D, de Wit S, et al. Comparative evaluation of NASBA HIV-1 RNA QT, AMPLICOR-HIV monitor, and QUANTIPLEX HIV RNA assay, three methods for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 1996;34:1058-64.
47. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 1997;387:183-8.
48. Cavert W, Notermans DW, Staskus K, et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science. 1997; 276:960-4.
49. Wong JK, Hezareh M, Günthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997;278:1291-4.
50. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997;278: 1295-8.
51. Ho DD. Time to hit HIV, early and hard. N Engl J Med. 1995;333:450-1.
52. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994;331:1173-80.
53. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med. 1996;335:1621-9.
54. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. MMWR Morb Mortal Wkly Rep. 1998;47(RR-2).
55. D'Aquila RT, Hughes MD, Johnson VA, et al. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. Ann Intern Med. 1996;124:1019-30.
56. Randomised trial of addition of lamivudine or lamivudine plus lovirride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. CAESAR Coordinating Committee. Lancet. 1997;349:1413-21.
57. Staszewski S, Loveday C, Picazo JJ, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. JAMA. 1996;276:111-7.
58. Katlama C, Ingrand D, Loveday C, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. JAMA. 1996;276:118-25.
59. + cells per cubic millimeter. N Engl J Med. 1995;333:1662-9.
60. Van Leeuwen R, Katlama C, Kitchen V, et al. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. J Infect Dis. 1995;171:1166-71.
61. Havlir DV, Eastman S, Gamst A, Richman DD. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J Virol. 1996;70:7894-9.
62. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors: a review for clinicians. JAMA. 1997;277:145-53.
63. McDonald CK, Kuritzkes DR. Human immunodeficiency virus type 1 protease inhibitors. Arch Intern Med. 1997;157:951-9.
64. Minkoff H, Augenbraun M. Antiretroviral therapy for pregnant women. Am J Obstet Gynecol. 1997;176:478-89.
65. Cao Y, Krogstad P, Korber BT, et al. Maternal HIV-1 viral load and vertical transmission of infection: the Ariel Project for the prevention of HIV transmission from mother to infant. Nat Med. 1997;3:549-52.
66. Luzuriaga K, Bryson Y, Krogstad P, et al. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. N Engl J Med. 1997;336:1343-9.
67. Kinloch-De Loës S, Hirschel BJ, Hoen B, et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med. 1995;333:408-13.
68. Lafeuillade A, Poggi C, Tamalet C, Profizi N, Tourres C, Costes O. Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection. J Infect Dis. 1997;175: 1051-5.
69. Hoen B, Harzic M, Fleury H, et al. ANRS053 trial of zidovudine (ZDV), lamivudine (3TC), and ritonavir combination in patients with symptomatic primary HIV-1 infection: preliminary results [Abstract]. In: Program and Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 22-26, 1997.
70. Tamalet C, Martin IP, Lafeuillade A. Viral load and genotypic resistance pattern in HIV-1 infected patients treated by a triple combination therapy including nucleoside and protease inhibitors (NIS and PIS) initiated at primary infection (PHI) [Abstract]. In: Program and Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 22-26, 1997.
71. Perrin L, Markowitz M, Calandra G, Chung M, and the MRL Acute HIV Infection Study Group. An open treatment study of acute HIV infection with zidovudine, lamivudine and indinavir sulfate [Abstract]. In: Program and Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 22-26, 1997.
72. Markowitz M, Cao Y, Vesanan M, et al. Recent HIV infection treated with AZT, 3TC, and a potent protease inhibitor [Abstract]. In: Program and Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 22-26, 1997.
73. + T cell responses associated with control of viremia. Science. 1997;278:1447-50.
74. Weiss RA. HIV receptors and the pathogenesis of AIDS. Science. 1996;272: 1885-6.
75. Moore JP, Trkola A, Dragic T. Co-receptors for HIV-1 entry. Curr Opin Immunol. 1997;9:551-62.
76. + T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med. 1995;332:143-9.
77. Darby SC, Weart DW, Giangrande PL, Spooner RJ, Rizza CR. Importance of age at infection with HIV-1 for survival and development of AIDS in UK haemophilia population. Lancet. 1996;347:1573-9.
78. Koot M, B van't Wout AB, Kootstra NA, EY de Goede R, Tersmette M, Schuitemaker H. Relation between changes in cellular load, evaluation of viral phenotype, and the clonal composition of virus populations in the course of human immunodeficiency virus type infection. J Infect Dis. 1996; 173:349-54.
79. Margolick JB, Muñoz A, Donnenberg AD, et al. Failure of T-cell homeostasis preceding AIDS in HIV-1 infection. Nat Med. 1995;7:674-80.
80. Shearer G, Clerici M. Early T-helper cell defects in HIV infection. AIDS. 1991;5:245-53.
81. + memory T cells by human immunodeficiency virus type 1: evidence for a role in selective T-cell functional defects observed in infected individuals. Proc Natl Acad Sci U S A. 1990;87: 6058-62.
82. + T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med. 1997;3:533-40.
83. Piatak M Jr, Yang LC, Luk KC, et al. Viral dynamics in primary HIV-1 infection [Letter]. Lancet. 1993;341:1099.
84. Tindall B, Cooper DA. Primary HIV infection: host responses and intervention strategies. AIDS. 1991;5:1-14.
85. Kinloch-de Loës S, de Saussure P, Saurat JH, Stalder H, Hirschel B, Perrin LH. Symptomatic primary infection due to human immunodeficiency virus type 1: review of 31 cases. Clin Infect Dis. 1993;17:59-65.
86. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med. 1996;125:257-64.
87. Piatak M, Saag MS, Yang LC, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science. 1993;259: 1749-54.
88. Cao Y, Ho DD, Todd J, et al. Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma. AIDS Res Hum Retroviruses. 1995;11:353-61.
89. Mansky LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol. 1995;69:5087-94.
90. Moutouh L, Corbeil J, Richman DD. Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure. Proc Natl Acad Sci U S A. 1996;93:6106-11.
91. de Jong MD, Veenstra J, Stilianakis NI, et al. Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine. Proc Natl Acad Sci U S A. 1996;93:5501-6.
92. Kozal MJ, Shah N, Shen N, et al. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide assays. Nat Med. 1996;2:753-9.
93. Schuurman R, Nijhuis M, van Leeuwen R, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis. 1995;171:1411-9.
94. Pluda JM, Cooley TP, Montaner JS, et al. A phase I/II study of 2′-deoxy-3′-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. J Infect Dis. 1995;171:1438-47.
95. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol. 1994; 68:1660-6.
96. Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 1995;374:569-71.
97. Condra JH, Holder DJ, Schleif WA, et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol. 1996;70:8270-6.
98. Imrie A, Beveridge A, Genn W, et al. Transmission of human immunodeficiency type 1 resistant to nevirapine and zidovudine. J Infect Dis. 1997; 175:1502-6.
99. Holodniy M, Mole L, Margolis D, et al. Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didanosine combination therapy. J Viral. 1995;69:3510-6.
100. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance in ritonavir. Nat Med. 1996;2:760-6.
101. Kelleher AD, Carr A, Zaunders J. Cooper DA, Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis. 1996;173: 321-9.
102. Jacobson MA, Zegans M, Pavan PR, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet. 1997;349:1443-5.
103. Whitcup SM, Fortin E, Nussenblatt RB, et al. Therapeutic effect of combination antiretroviral therapy on Cytomegalovirus retinitis [Letter]. JAMA. 1997;277:1519-20.
104. Hicks CB, Myers SA, Giner J. Resolution of intractable molluscum contagiosum in a human immunodeficiency virus-infected patient after institution of antiretroviral therapy with ritonavir. Clin Infect Dis. 1997;24:1023-5.
105. Benhamou Y, Bochet MV, Carriere J, et al. Effects of triple antiretroviral therapies including a HIV protease inhibitor on chronic intestinal cryptosporidiosis and microsporidiosis in HIV-infected patients [Abstract]. In: Program and Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections Washington, DC, January 22-26, 1997.
106. Carr A, Cooper DA. Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor [Letter]. Lancet. 1997;349: 995-6.
107. Phillips P, Zala C, Rouleau D, Montaner JS. Mycobacterial lymphadenitis: can highly active antiretroviral therapy (HAART) unmask subclinical infection? [Abstract] In: Program and Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 22-26, 1997.